HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 23050.0
(-1.5%)
KRW 23050.0
(-1.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 53.19 Billion KRW | -5.42% |
| 2022 | 56.24 Billion KRW | 14.22% |
| 2021 | 49.24 Billion KRW | -26.27% |
| 2020 | 66.79 Billion KRW | 139.05% |
| 2019 | 27.94 Billion KRW | 43.85% |
| 2018 | 19.42 Billion KRW | -15.71% |
| 2017 | 23.04 Billion KRW | -1.92% |
| 2016 | 23.49 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 41.97 Billion KRW | -7.73% |
| 2024 Q1 | 45.48 Billion KRW | -14.49% |
| 2023 Q2 | 59.36 Billion KRW | -1.17% |
| 2023 Q4 | 53.19 Billion KRW | 0.23% |
| 2023 Q3 | 53.07 Billion KRW | -10.59% |
| 2023 FY | 53.19 Billion KRW | -5.42% |
| 2023 Q1 | 60.06 Billion KRW | 6.78% |
| 2022 Q2 | 39.74 Billion KRW | -20.68% |
| 2022 Q4 | 56.24 Billion KRW | -3.34% |
| 2022 Q1 | 50.1 Billion KRW | 1.74% |
| 2022 Q3 | 58.19 Billion KRW | 46.42% |
| 2021 Q4 | 49.24 Billion KRW | -34.81% |
| 2021 Q3 | 75.54 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | -32.896% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 79.924% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 86.938% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 79.8% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -214.431% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -142.752% |
| Boditech Med Inc. | 30.48 Billion KRW | -74.506% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 21.565% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -496.472% |
| Huons Co., Ltd. | 206.87 Billion KRW | 74.285% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -142.406% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -39.292% |